In this week's podcast episode with Maria Sampalis, OD, shares how she got started with her practice's marketing.

The U.S. Attorney' Office Eastern District of Texas reported Kleiman Evangelista Eye Centers has agreed to pay $2,902,505 to resolve False Claims Act allegations that it offered and paid kickbacks to optometrists.

Technologies that improve treatment of ONHD and similar pathologies.

Investigators reported that moderate to severe Meibomian gland dysfunction (MGD) was treated successfully with a 3-week course of weekly oral azithromycin that was equivalent to a 6-week course of oral doxycyclin.

Imaging can elucidate visual prognosis and disease progression risk.

Jennifer Tsai, OD, tells us how to start the conversation with patients about dual-wear, and the benefits of this from the patient and provider perspective.

Mitch Ibach, OD, FAOO, tells us about the current corneal cross-linking treatments, as well as those on the horizon.

A look back on what happened in optometry during the week of March 20-March 24.

Katie Gilbert-Spear, OD, JD, MPH, gives an overview on the importance of referring keratoconus patients to receive FDA-approved corneal cross-linking.

In this first study to provide an in-depth analysis of the retinal proteins, researchers conducted histopathologic and biochemical studies of postmortem retina and brain tissues from 86 human donors.

Self-reported survey data “showed that a majority reported reductions in visual recognition and navigation abilities,” the researchers reported.

In this week's podcast episode with Maria Sampalis, OD, hear how to differentiate between branding and marketing.

REACH operates with three objectives: 1) eliminate barriers to eye health for school children; 2) improve the quality of school eye health services; and 3) create a positive, sustainable environment at schools where eye health services are provided, ensuring children feel comfortable to access these services.

On World Optometry Day 2023, we asked experts to share what this industry means to them.

The second pivotal phase 3 data on NOV03 (perfluorohexyloctane) show that NOV30 consistently met primary endpoints for signs and symptoms of dry eye disease associated with Meibomian gland dysfunction.

Following the enrollment completion for Brimochol PF, topline Phase 3 data for the presbyopia candidate is expected in Q2 2023.